Aggressive Subclass Of Prostate Cancer May Be Driven By Estrogen Signaling - May 27 JNCI
Main Category: Prostate / Prostate CancerAlso Included In: Endocrinology; Cancer / Oncology
Article Date: 28 May 2008 - 6:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Aggressive prostate cancers that harbor a particular gene fusion are a distinct molecular subtype of the disease and their growth may be regulated by estrogen signaling.
Prostate cancers that carry the TMPRSS2-ERG gene fusion, which links the regulatory region of one gene to the protein-coding region of another, tend to be aggressive. The molecular mechanism by which the fusion gene impacts pathogenesis has been unknown.
Mark Rubin, M.D., of Weill Cornell Medical College in New York and colleagues examined the expression pattern of 6,144 genes in tumor samples from 455 patients from the Swedish Watchful Waiting cohort and the Physicians Health Study cohort from the United States.
Overall the investigators found that 103 tumors contained the fusion gene. When they compared the gene expression pattern in the tumors with the TMPRSS2-ERG fusion and those lacking it, they identified an 87-gene signature that correlated with the fusion gene. Many of the genes in the signature respond to estrogen signaling. In vitro experiments with prostate cancer cell lines indicated that drugs that stimulate one type of estrogen receptor promoted cancer cell growth, while drugs that activated another type of estrogen receptor increased cell death.
"Our results suggest a mechanism by which prostate cancers might develop androgen independence from an initial androgen-dependent state," the authors write.
###
Contact: Andrew Klein, office of public affairs, Weill Cornell Medical College
http://www.med.cornell.edu
Also in May 27 JNCI:
Overlapping Tumor Suppressor Genes Independently Involved In Melanoma
No Association Found Between Vitamin D Concentration In Blood And Risk Of Prostate Cancer
Antioxidant Supplements May Lessen Benefit Of Radiation And Chemotherapy
The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jnci.oxfordjournals.org/.
Source:
Liz Savage
Journal of the National Cancer Institute
Visit our prostate / prostate cancer section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/108992.php>
APA
http://www.medicalnewstoday.com/releases/108992.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



